Medtronic Evolut™ TAVR

Valve design makes a difference.

From day one, this valve was designed specifically for transcatheter AVR with performance as the driving force.


Exclamation icon Indications, Safety, and Warnings
Women in small circle
Valve performance

Durability starts with design.


Built on the original CoreValve™ platform, Evolut™ TAVR is engineered with specific design elements to promote sustained valve performance with consistently large EOAs and low gradients over time.1,2
Supra-annular mounting image

Supra-annular valve: keeps functional portion of the valve above the annulus for lower gradients and reduced workload on the left ventricle.3,4

External tissue wrap image

External tissue wrap: increases surface contact with native anatomy, providing advanced sealing.5

Four-time larger windows image

Larger frame windows: four times larger windows to enable lifetime management solutions such as coronary access.6

TAVR risks may include, but are not limited to, death, stroke, damage to arteries, bleeding, and need for permanent pacemaker.

Fundamental differences in design exist among TAVR devices.


Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance.‡,7


Valve design makes a difference.

Diagram Evolut TAVR System

Evolut™ TAVR

Supra-annular |More Room3


Working portion of the valve is positioned up and away from the annulus, increasing forward flow, reducing ventricular resistance, and alleviating leaflet stress.3,4,8
Diagram SAPIEN TAVR System

SAPIEN™* TAVR

Intra-annular |Less Room3


Working portion of the valve is positioned within the native annulus and frame, decreasing forward flow, increasing ventricular resistance, resulting in increased leaflet stress.3,4,8

‡ Valve performance as defined as freedom from bioprosthetic valve dysfunction (BVD) through 12 months. BVD is defined as a composite including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction (severe prothesis-patient mismatch or ≥ moderate aortic regurgitation), clinical thrombosis, endocarditis, and aortic valve reintervention.


  1. Herrmann HC. SMART 2-year data update. Presented at CRT 2025; March 9, 2025, Washington D.C.
  2. Forrest JK, Yakubov SJ, Deeb GM, et al. Low Risk Trial Investigators. 5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2025 Apr 22;85(15):1523-1532.
  3. Abdelghani M, Mankerious N, Allali A, et al. Bioprosthetic valve performance after transcatheter aortic valve replacement with self-expanding versus balloon-expandable valves in large versus small aortic valve annuli: Insights from the CHOICE Trial and the CHOICE-Extend Registry. JACC Cardiovasc Interv. 2018;11(24):2507–2518.
  4. Dahou A, Mahjoub H, Pibarot P. Prosthesis-Patient Mismatch After Aortic Valve Replacement. Curr Treat Options Cardiovasc Med. 2016 Nov;18(11):67.
  5. 90-day porcine GLP Evolut R study. Results may not be indicative of clinical performance. Medtronic data on file.
  6. Medtronic computational data model on file compared to the Evolut platform. Bench top computational model may not be indicative of clinical performance. FX+ test report: D01106198 Rev A.
  7. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024.
  8. Stanova V, Rieu R, Thollon L, et al. Leaflet Mechanical Stress in Different Designs and Generations of Transcatheter Aortic Valves: An in Vitro Study. Struct Heart. 2023 Dec 19;8(2):100262.

™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

UC202600896 EN 06/2025